/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Roivant Sciences Ltd. Share Price Today: Live Updates & Key Insights

Roivant Sciences Ltd. share price today is $28.38, up -3.48%. The stock opened at $29.35 against the previous close of $29.58, with an intraday high of $29.35 and low of $28.285.

Roivant Sciences Ltd. Share Price Chart

style
pb-0

Roivant Sciences Ltd.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Roivant Sciences Ltd. Share Price Performance

$28.38 -0.0348(-3.48%) ROIV at 13 Mar 2026 03:04 PM Biotechnology
Lowest Today 28.285
Highest Today 29.35
Today’s Open 29.35
Prev. Close 29.58
52 Week High 30.33
52 Week Low 8.73
Day’s Range: Low 28.285 High 29.35
52-Week Range: Low 8.73 High 30.33
1 day return -
1 Week return -0.78
1 month return +7.95
3 month return +30.5
6 month return +105.02
1 year return +174.35
3 year return +264.28
5 year return +190.83
10 year return -

Roivant Sciences Ltd. Institutional Holdings

FMR Inc 9.19

Morgan Stanley - Brokerage Accounts 6.19

Vanguard Group Inc 5.88

SB INVESTMENT ADVISERS (UK) LTD 5.63

BlackRock Inc 5.55

Qvt Financial LP 4.11

Fidelity Growth Compy Commingled Pl S 3.84

Fidelity Growth Company Fund 2.88

State Street Corp 2.61

Vanguard Total Stock Mkt Idx Inv 2.01

iShares Core S&P Mid-Cap ETF 1.98

Two Seas Capital LP 1.64

Adage Capital Partners Gp LLC 1.49

Vanguard Small Cap Index 1.43

Dimensional Fund Advisors, Inc. 1.29

Rubric Capital Management LP 1.26

Geode Capital Management, LLC 1.15

Patient Square Capital LP 1.14

Perceptive Advisors LLC 1.03

Assenagon Asset Management SA 0.97

Viking Global Investors LP 0.90

Morgan Stanley Growth 0.89

Morgan Stanley Growth SMA 0.89

Morgan Stanley Inst Growth I 0.89

MS INVF US Advantage I 0.87

Fidelity Growth Company K6 0.83

Vanguard Small Cap Growth Index Inv 0.80

Baker Bros Advisors LP 0.78

Fidelity Series Growth Company 0.73

NORGES BANK 0.73

MS INVF US Growth I 0.71

State Street® SPDR® S&P® Biotech ETF 0.67

Vanguard Institutional Extnd Mkt Idx Tr 0.66

Bank of New York Mellon Corp 0.65

Marshall Wace Asset Management Ltd 0.56

BrighthouseI Morgan Stanley Discovery B 0.53

iShares Biotechnology ETF 0.45

State Street® SPDR® S&P MIDCAP 400® ETF 0.44

T. Rowe Price Health Sciences 0.43

Morgan Stanley Insight 0.41

Roivant Sciences Ltd. Market Status

Strong Buy: 6

Buy: 3

Hold: 1

Sell: 0

Strong Sell: 0

Roivant Sciences Ltd. Fundamentals

Market Cap 21170.44 M

PB Ratio 4.9588

PE Ratio 0.0

Enterprise Value 16749.40 M

Total Assets 5436.94 M

Volume 4061737

Roivant Sciences Ltd. Company Financials

Annual Revenue FY25:29053000 29.1M, FY24:124795000 124.8M, FY23:61280000 61.3M, FY22:55286000 55.3M, FY21:23795000 23.8M

Annual Profit FY25:28142000 28.1M, FY24:96831000 96.8M, FY23:48152000 48.2M, FY22:46320000 46.3M, FY21:21738000 21.7M

Annual Net worth FY25:-171981000 -172.0M, FY24:4348926000 4348.9M, FY23:-1230024000 -1230.0M, FY22:-924116000 -924.1M, FY21:-900233000 -900.2M

Quarterly Revenue Q4/2025:1999000 2.0M, Q3/2025:1571000 1.6M, Q2/2025:2170000 2.2M, Q1/2025:7570000 7.6M, Q4/2024:9018000 9.0M

Quarterly Profit Q4/2025:1299000 1.3M, Q3/2025:1460000 1.5M, Q2/2025:2016000 2.0M, Q1/2025:7365000 7.4M, Q4/2024:8759000 8.8M

Quarterly Net worth Q4/2025:-265891000 -265.9M, Q3/2025:-113519000 -113.5M, Q2/2025:-223355000 -223.4M, Q1/2025:-206475000 -206.5M, Q4/2024:169381000 169.4M

About Roivant Sciences Ltd. & investment objective

Company Information Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Organisation Biotechnology

Employees 750

Industry Biotechnology

CEO Dr. Eric Venker M.D., Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow